Intraocular Inflammation with faricimab: insights from Manufacturer and User Facility Device Experience (MAUDE) database
<p dir="ltr">Since its introduction in 2019, brolucizumab’s safety has been called into question due to numerous reports of IOI following intravitreal injections. In 2020, post-marketing data showed that there was a confirmed safety alarm of severe ocular adverse events such as retin...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | |
| منشور في: |
2024
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|